Protalix BioTherapeutics (NYSE:PLX) Given "Buy" Rating at HC Wainwright

Key Points

• HC Wainwright reiterated a “buy” rating on Protalix BioTherapeutics and set a $12 price target, implying approximately 361% upside from the stock’s $2.60 price.
• Protalix shares traded near the middle of their 52-week range, with a market capitalization of about $210 million and negative earnings reflected in a P/E ratio of -20.04.
• Institutional ownership stands at 16.53%, with BlackRock initiating a roughly $9.4 million position and several other investment firms increasing their holdings.

Protalix BioTherapeutics (NYSE:PLX - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $12.00 price target on the stock. HC Wainwright's target price indicates a potential upside of 360.65% from the company's current price.

Protalix BioTherapeutics Stock Performance

Shares of NYSE:PLX traded down $0.04 during trading on Wednesday, hitting $2.60. The company's stock had a trading volume of 148,646 shares, compared to its average volume of 919,864. The business has a 50 day moving average price of $2.41 and a two-hundred day moving average price of $2.33. The company has a market capitalization of $209.89 million, a PE ratio of -20.04 and a beta of 0.02. Protalix BioTherapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $3.19.

Hedge Funds Weigh In On Protalix BioTherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Protalix BioTherapeutics in the second quarter valued at approximately $9,429,000. Geode Capital Management LLC grew its holdings in Protalix BioTherapeutics by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 830,054 shares of the company's stock worth $1,494,000 after acquiring an additional 10,277 shares in the last quarter. State Street Corp grew its holdings in Protalix BioTherapeutics by 17.4% during the 4th quarter. State Street Corp now owns 585,261 shares of the company's stock worth $1,053,000 after acquiring an additional 86,714 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Protalix BioTherapeutics by 932.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 296,843 shares of the company's stock valued at $644,000 after purchasing an additional 268,099 shares during the last quarter. Finally, Jane Street Group LLC increased its position in shares of Protalix BioTherapeutics by 159.0% in the 1st quarter. Jane Street Group LLC now owns 294,318 shares of the company's stock valued at $753,000 after purchasing an additional 180,702 shares during the last quarter. 16.53% of the stock is owned by institutional investors and hedge funds.

About Protalix BioTherapeutics

Protalix BioTherapeutics NYSE: PLX is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix's core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company's first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.